T · 6190.T
PhoenixBio Co., Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Higashihiroshima 739-0046
- Website
- phoenixbio.co.jp
Price · as of 2025-03-31
$436.00
Market cap 1.98B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $476.38 | +9.26% |
| Intrinsic Value(DCF) | $236.25 | -45.81% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $179.17 | -58.91% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $821.00 | ||||
| 2021 | $611.00 | $267.95 | $149.83 | $0.00 | $992.60 |
| 2022 | $617.00 | $798.60 | $4,106.42 | $0.00 | $0.00 |
| 2023 | $564.00 | $320.28 | $20,652.79 | $1,171.99 | $9,571.29 |
| 2024 | $489.00 | $847.52 | $225.45 | $510.21 | $0.00 |
| 2025 | $380.00 | $476.38 | $165.50 | $0.00 | $179.17 |
AI valuation
Our deep-learning model estimates PhoenixBio Co., Ltd.'s (6190.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $476.38
- Current price
- $436.00
- AI upside
- +9.26%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$236.25
-45.81% upside
Graham-Dodd
—
— upside
Graham Formula
$179.17
-58.91% upside
About PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
- CEO
- Takashi Shimada
- Employees
- 70
- Beta
- 0.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($236.25 ÷ $436.00) − 1 = -45.81% (DCF, example).